Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entecavir + carvedilol
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of entecavir, a nucleoside analogue used to treat chronic hepatitis B, and carvedilol, a non-selective beta-adrenergic antagonist used to treat heart failure, hypertension, and left ventricular dysfunction. While one source indicates no interaction is expected between these medications, another suggests that entecavir may decrease the metabolism of carvedilol, potentially increasing carvedilol levels.
02
Targets
HBV Pol (Hepatitis B virus polymerase)ADRA1A (α1A)ADRB2 (β2)ADRB1 (β1)
Beyond the preview
Go deeper on entecavir + carvedilol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entecavir + carvedilol.